This is a working overview of lyophilized solid, written for readers who want more than a one-paragraph summary but less than a textbook.
This page was last updated on 2026-03-14 and is reviewed periodically as new material appears.
Routine handling calls for minimizing freeze-thaw cycles and preparing solutions shortly before use. Glass or inert plastic containers reduce adsorption and metal leaching. Working stocks are often kept at 2–8 °C for short periods, while long-term reference material stays at −20 °C or below. Light protection is prudent because prolonged exposure may accelerate oxidation of the peptide. Documentation of lot number, concentration, and preparation date supports reproducibility in laboratory work.
Analytical verification typically combines reversed-phase high-performance liquid chromatography with ultraviolet-visible detection. The copper complex absorbs visible light near 600–630 nm, giving a characteristic blue signal. Mass spectrometry confirms molecular mass and can detect free peptide or mismatched copper stoichiometry. Copper content is often measured independently by inductively coupled plasma mass spectrometry or atomic absorption spectroscopy. Purity, counterion identity, and residual solvents are additional quality-control parameters that methods may address.
Solid GHK-Cu is generally stored as a dry powder under frozen conditions to limit degradation. The peptide bond can hydrolyze, and the copper center can be displaced by strong chelators such as EDTA. Aqueous solutions are less stable than the solid and may lose color or form precipitates over time. Temperature, pH, and oxygen exposure are the main variables that affect shelf life. Neutral to slightly acidic conditions tend to preserve the complex better than strongly alkaline media.
GHK-Cu is a coordination complex formed between the tripeptide glycyl-L-histidyl-L-lysine and a copper(II) ion. The peptide binds copper through its histidine imidazole nitrogen, its terminal amino group, and a deprotonated amide nitrogen, creating a stable chelate ring. The resulting complex carries a distinctive blue to blue-violet color, which arises from copper d-d electronic transitions. In the solid state it is usually handled as a powder, while in solution the complex can dissociate and re-form depending on pH and competing ligands. The name copper tripeptide-1 is widely used in ingredient listings.
The tripeptide was first isolated from a human plasma filtrate in 1973 during studies of tissue repair factors. Later work detected the free peptide and its copper complex in saliva, urine, and wound fluid, suggesting a natural role in tissue remodeling. Plasma concentrations reported in early literature decline with age, a pattern often cited in discussions of skin aging. Whether these endogenous levels are directly functional or largely incidental remains an open question. The peptide sequence is conserved across mammalian species.
Material described in research and cosmetic supply chains is typically a synthetic peptide supplied as a lyophilized powder. Purity is commonly reported through chromatographic separation, often at 95 percent or higher, while copper content is confirmed by separate elemental analysis. Batch variation in color and solubility can reflect residual counter-ions, moisture, or partial oxidation of the peptide. Because the complex is not a single regulatory entity, specifications differ between suppliers and are not standardized internationally.
| Property | Value | Notes |
|---|---|---|
| Physical state | Blue-violet solid | Typically supplied as lyophilized powder |
| Storage temperature | −20 °C or below | Desiccated, protected from light |
| Working stability | Hours to days at 2–8 °C | Depends on concentration and buffer |
| Identity test | RP-HPLC with UV-Vis | Visible absorbance near 600–630 nm |
| Copper assay | ICP-MS or AAS | Metal content confirms stoichiometry |
Dry material is normally held cold, commonly at -20 °C for long-term storage and 2 to 8 °C for working quantities, protected from light and moisture. Vials should be allowed to reach room temperature before opening so that condensation does not form on the powder. In liquid formulations the complex is generally kept near neutral to slightly acidic pH, because strongly alkaline conditions favour precipitation of copper hydroxide. Antioxidants or chelate-stabilising excipients are often added, though the specific approaches are proprietary and rarely published in detail.
Identity and purity are assessed mainly by reversed-phase high-performance liquid chromatography with ultraviolet detection, often paired with mass spectrometry to confirm the expected mass. Copper content is measured separately by inductively coupled plasma optical emission spectrometry or atomic absorption spectroscopy, because the peptide assay alone does not establish the metal-to-peptide ratio. Visible spectroscopy provides a rapid check on complex integrity through the absorption band in the visible region. Agreement between the peptide assay and the copper assay is the practical test of whether a sample is the intended complex rather than a mixture.
Aqueous solutions of GHK-Cu are less stable than the dry powder. The peptide backbone is vulnerable to hydrolysis at extreme pH, and copper can be stripped from the complex by strong chelating agents such as EDTA or citrate. Oxidising agents and high concentrations of ascorbic acid can reduce copper(II) and change the complex, which is one reason formulators often keep such ingredients in separate phases. How quickly these changes occur under real storage conditions depends on pH, buffer, temperature and packaging, and quantitative data on the subject are limited.
The molecular weight and charge of GHK-Cu depend on the pH and the number of coordinated ligands. At neutral pH, the peptide typically binds one copper ion, but ternary complexes with other biomolecules can form. Spectroscopic methods such as electron paramagnetic resonance and circular dichroism are used to study the coordination environment. Reports on the exact geometry vary because the complex is dynamic in solution. Researchers often use synthetic GHK-Cu rather than extracted material to control stoichiometry and purity.
GHK-Cu is a coordination complex formed from the tripeptide glycyl-L-histidyl-L-lysine and a copper(II) ion. The peptide binds copper through its histidine imidazole nitrogen, the terminal amino group, and the deprotonated amide nitrogen. This arrangement creates a square-planar or distorted geometry around the metal center, depending on pH and the presence of competing ligands. The complex occurs naturally in human plasma, saliva, and urine at low concentrations, and its sequence is conserved across many vertebrate species.
Discovery of GHK is generally attributed to work in the 1970s that isolated a plasma factor influencing liver cell behavior. Subsequent studies identified the copper-binding tripeptide and its ability to chelate copper with high affinity. Early reports linked the complex to wound healing and tissue remodeling in animal models. The free peptide and the copper-bound form have different properties, so the two are distinguished in the literature. Whether endogenous GHK-Cu serves a single primary physiological role remains an open question.
The sequence now called GHK was first reported in the early 1970s after isolation from human plasma, where it was noted to influence liver cell behavior in laboratory preparations. Later work described a copper-binding form and its activity in fibroblast and wound-model experiments. Review articles frequently group the substance with other copper peptides. Concentrations in blood appear to fall with age in several small surveys, although the reason for this trend is not settled. Whether such a decline carries functional consequences remains an open question.
Published work on GHK-Cu concentrates largely on cell culture systems rather than whole organisms. Frequently used endpoints include collagen synthesis, expression of matrix metalloproteinases, and migration of fibroblasts. Some reports describe antioxidant behavior, while others stress delivery of copper into cells. These mechanisms are proposed rather than demonstrated, and the relative weight of each pathway is unclear. Human trials are few and generally small, so laboratory findings should not be read as confirmed clinical results.
Peptide nucleic acid (PNA) is an artificially synthesized polymer similar to DNA or RNA. Synthetic peptide nucleic acid oligomers have been used in recent years in molecular biology procedures, diagnostic assays, and antisense therapies. Due to their higher binding strength, it is not necessary to design long PNA oligomers for use in these roles, which usually require oligonucleotide probes of 20–25 bases. The main concern of the length of the PNA-oligomers is to guarantee the specificity. PNA oligomers also show greater specificity in binding to complementary DNAs, with a PNA/DNA base mismatch being more destabilizing than a similar mismatch in a DNA/DNA duplex. This binding strength and specificity also applies to PNA/RNA duplexes. PNAs are not easily recognized by either nucleases or proteases, making them resistant to degradation by enzymes. PNAs are also stable over a wide pH range. Though an unmodified PNA cannot readily cross the cell membrane to enter the cytosol, covalent coupling of a cell penetrating peptide to a PNA can improve cytosolic delivery. PNA is not known to occur naturally but N-(2-aminoethyl)-glycine (AEG), the backbone of PNA, has been hypothesized to be an early form of genetic molecule for life on Earth and is produced by cyanobacteria and is a neurotoxin. PNA was invented by Peter E. Nielsen (Univ. Copenhagen), Michael Egholm (Univ. Copenhagen), Rolf H. Berg (Risø National Lab), and Ole Buchardt (Univ. Copenhagen) in 1991.
==== Alpidem ==== Alpidem is a nonbenzodiazepine anxiolytic with similar anxiolytic effectiveness as benzodiazepines but reduced sedation and cognitive, memory, and motor impairment. It was marketed briefly in France but was withdrawn from the market due to liver toxicity.
However, there was indication of a small effect in improving depressive symptoms that approached trend-level significance. lisdexamfetamine was well-tolerated in the meta-analysis. The quantity of evidence was limited, with only four trials included. In a subsequent 2022 network meta-analysis, lisdexamfetamine was significantly effective as an antidepressant augmentation for treatment-resistant depression. Although lisdexamfetamine has shown limited effectiveness in the treatment of depression in clinical trials, a phase II clinical study found that the addition of lisdexamfetamine to an antidepressant improved executive dysfunction in people with mild major depressive disorder but persisting executive dysfunction.
Sources: en.wikipedia.org
== Evolution == There are five groups of TNNI in vertebrates, the extra two known as TNNI4 and TNNI5 (only found in non-amniotes). They are more similar to TNNI1 than to TNNI2 and TNNI3. Likewise, there are four groups of TNNT in vertebrates, with TNNT4 (only found in cartilaginous fishes, ray-finned fishes and lungfish) most closely resembling TNNT2. In most vertebrates and some non-vertebrate chordates, TNNI and TNNT genes tend to occur in pairs next to each other. It is likely that an ancestor to vertebrates had one such pair, which was duplicated into four during the two rounds of whole-genome duplication in early vertebrate evolution, with TNNT5 arising as an additional tandem dupliaction of TNNT4. Most vertebrates express TNNI1 and/or TNNI5 in the heart, whereas adult tetrapods (such as mammals) use TNNI3. Embryonic mammals use TNNI1 in the heart. In humans and teterapods in general, TNNI3 differ from the other TnI genes by having an N-termianl extension; a strikingly similar extension is found in the TNNI5 of cartilaginous, non-teleost ray-finned, and sarcopterygian fishes. Ray finned fishes do not have TNNI3 at all. Substituting TNNI3 for TNNI1 may confer increased tolerance to acidosis. Considering the similarity between TNNI and TNNT, the gene pair may have been the result of an even more ancient tandem duplication event.
=== Solar and Soul Train Records Legacy Today === The Solar Records legacy continues today with the Solar Records and Soul Train Records brands licensed to Solar Legacy Entertainment Ltd and Galaxy of Stars Ltd. The Solar Legacy Entertainment Ltd company includes attorney at law Virgil Roberts who previously was president and legal counsel for Solar Records and Dick Griffey. Solar Legacy Entertainment also acquired music catalog rights to historic master recordings and also new music catalogs. Other ventures include the continuation of the 'Soul Train Club' radio show which has been broadcasting on Solar Radio since 2017. As of 2023 Galaxy of Stars Ltd oversees the live entertainment and music interests of the brands which includes the Soul Train Club and Solar Records. In December 2023 Solar entered into a TV and Film publishing deal due to be announced in 2024. Earmarked for release in 2024 is a new single by Kimberly Brown of Sounds of Blackness. As of 2024 Virgil Roberts and Jessie Tsang on behalf of Solar Legacy Entertainment Ltd, entered into a deal with the famed Hollywood author, TV and film producer Tina Andrews for a Dick Griffey and Solar Records motion picture deal. Solar Legacy Entertainment Ltd also own a number of master recording rights to recordings by Soul Train Gang, Carrie Lucas, Klymaxx, Sunbear, Snoop Dogg and Dr Dre and the sound track to the film Deep Cover. Part of Solar's new catalog includes new music by Leon Sylvers III, Dana Meyers, Freddie Lee Peterkin, Brian K Morgan and Katie Goulet and Dick Griffey's grandson Kid3rd.
=== Methods of assessment === An increase in prothrombin time, a coagulation assay, has been used as an indicator of vitamin K status, but it lacks sufficient sensitivity and specificity for this application. Serum phylloquinone is the most commonly used marker of vitamin K status. Concentrations <0.15 μg/L are indicative of deficiency. Disadvantages include exclusion of the other vitamin K vitamers and interference from recent dietary intake. Vitamin K is required for the gamma-carboxylation of specific glutamic acid residues within the Gla domain of the 17 vitamin K–dependent proteins. Thus, a rise in uncarboxylated versions of these proteins is an indirect but sensitive and specific marker for vitamin K deficiency.
== Soluble TCR == A soluble TCR is a TCR that has been made water-soluble using protein engineering. Such a protein is based on changing an existing TCR's chains to remove the transmembrane portions, leaving only the extracellular part. A number of techniques from protein engineering are then used to stabilize the complex and improve its binding characteristics. A soluble TCR can be used as an antigen-binding module, much like how monoclonal antibodies are used in medicine. Their advantage over antibodies is that they make use of the MHC/HLA display mechanism, allowing them to detect not only extracellular antigens, but also fragments of intracellular ones. On the other hand, they also face some restrictions in terms of applicable HLA genotypes due to them being made to target the complex of a MHC protein with the antigen fragment. One idea for overcoming this restriction is to instead target monomorphic HLA-like molecules such as HLA-E, MHC-related protein 1 (MR1) and cluster of differentiation 1 a, b, c and d (CD1a, CD1b, CD1c or CD1d). An example of a protein derived from soluble TCR is tebentafusp, approved by the US FDA in 2022. This designed protein contains a soluble TCR (αβ) targeting a fragment of gp100 presented by HLA-A*02:01 connected to a ScFv that binds CD3. As a result it causes T cells to activate in the vicinity of cells that present gp100, acting as a molecular glue (a bi-specific T-cell engager in the broad sense). It is only applicable to people with the HLA-A*02:01 genotype.
Sources: en.wikipedia.org
Dry powder is typically stored frozen at −20 °C or lower, protected from moisture and light. Short-term working amounts may be kept refrigerated. Avoiding repeated temperature changes helps preserve the material.
Reversed-phase HPLC with UV-visible detection is common because the copper complex absorbs visible light. Mass spectrometry provides molecular mass confirmation. Copper-specific methods such as ICP-MS quantify the metal content.
The blue color comes from copper-ligand interactions. Displacement of copper by chelators or changes in pH can shift or diminish the color. Such changes often indicate that the complex has been altered.
It is a complex of the tripeptide glycyl-L-histidyl-L-lysine with a copper(II) ion. The peptide coordinates the metal through its histidine, amino terminus, and an amide nitrogen. It is often listed simply as copper tripeptide-1.